COMPANY REGISTRATION NUMBER 6310215 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CONSOLIDATED FINANCIAL STATEMENTS 31 DECEMBER 2023 Charlty Number 1121258
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE FINANCIAL STATEMENTS YEAR ENDED 31 DECEMBER 2023 COEr$ PAGE chrMan'S Statement Tnjstees Annual Rèp¢xt Indépendent auditols rewrt to the rnembers 14 ConsolKlated Statsrnent of finantyal activrbes IiTKorporating th& incorne and expenditure acwuntl 17 Charty Statement of finanaal actwities (incorporang the incomè and expendttur8 accounti 18 Consolidated Bdance sheet 19 Charty ance shget 20 Consolidated Statoment of Cashfiows Charity statement of Cashllows Note5 to the ffinan statements 23
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHAIRMAN'S STATEMENT YEAR ENDED 31 DECEMBER 2023 Thisyearwelebrated Our annwersary. What berdn with a discovery relatingto sugarstructures on primaryturnour5 has matured into a branch of science known todayas Glycobiology. ourfvndrdlng has ofcourse Changed dramaticallyovertheyearstoo, butre3ssurlnethe SweetPeasthat PatLeathem oKe sold from her garden to raisevital fundsto start the charity are availabletoday through ouronline shop. We congratulated longtirne Trustee Jeanne Chattoe for bèing recognlsed in the Kings Birthday Honours Ust. Jeanne was awarded the British Empire Medal for Charitsble Services to People wtth Cancer. 3 reflection on hertirelessfundraising that began afterthe Ios5 of her sister Delia 30 years a80. We appo¢nted Dr Una Hacker a5 our latest Junior Research Fellow at Oriel College in Oxford. tina 15 a postdoctoral research fellow at the Department of Oncology. We will be 5UPPOrting her work for 3 years as she develops new imagingtools and strategiesto detect and stratify Icategorisel hypoxia levels in breast Canr. Particularly in breast canTrr. tumour5 that are more hypoxic have been shown to be rnore aggressive and resistant to treatments. leading to worse outcomes for the patients. The impact of people getting physically artive during the pandemic was clearly evident in 2023. rch uncertainty around mixing in larger groups largety diminishin& we have seen a huge increase thisyear in funds raised frorn sports and challenge events a5 well asfrom various sportsteams. Golf, football and Rugby Clubs a150 represented a signific3nt proportion of funds raised in the community space throL¢ghout 2023, further illustrating the role physlcal activity has had in boostingfundraising thi5year. We recognise the need to continually develop our staff. TIning in digital skills have alreadv begun the integrating oursystems to IMpe the supporter experience. On behalf of the boèrd of trustees l extend ourthanks to everyone involved, fortheir 8enerosity. theirtime and their dedication to our cause, a future free from breast cancer. Richard Bahu Chair of Trustees
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors. Report) fcoftknue YEAR ENDED 31 DECEMBER 2023 The tnjstees, who are 0 for the wrpjses Qf wmpany law, present their report and the financi slatements of the tharity forthe year ended 31 DeMber2o23. 0ECTIVEs AND AcnvmES Against Breast Cancer IABCI was established to frJnd unique research into secondary breast caer, tnwn ause of breaSt<anr rela deaths. The secondary spread of breast cancer. or metastasis, is Current an incurable condition whh can occur in up to 40% 01 breast cancer Wlents, someb'mES year5 after a primary diagnosis and Ireatrnenl, which clarns the lives of 12,000 people each year the UK. BC rwse money lo increase the surviv rates of bre cancer patients by supportTng researd) in 4 areas,. 11 to devdop Irealm&nts for secondary breast cancer, uhimately avaccine 21 lo develop loolsforthe earlierdiagnos¢ of sondary breast nCer3) to understsnd which diet and lifestyle laciors impact risk of rewrrence or spread 41 to provKlea at[Orr forcommunication iodrivelhe ¥Lienlificfield forward. ABC founder and br8a8t¢ancer researcher Dr. Anthony Leathem discoverwj a difference in thÈ sugar architerlur&- th¢ gty¢obiology- on aggresswe breast carttrs compared lo le55 irwasive ryP8S ol brfr (er. Public Benefit The Trustees confirm Ihat Ihey have mPlIed %Mth the duty ef sethn 17 of the Charilies Act 2011 to have due regard to the guidarte issued byThe Charty Commission on public bewfft. The charitae purpose forth& chatty thin the meanino of the Act Is enshrined ¥ThIn its Oblte5 staled above. The holist approach to our research strateoy tSISt0 benefit the 600,000 people currenuy MrvJ adiagAosi5 of bréasttwcerin the UK and prerficted lo rise lo 1.2 mlllion by 2030. Our research falls und8r main themes.. Prevention, DeteLIKin, and Therapy. While the Therapeuttc AntibDdy programme priniapally focusses on Therapy, our research into Prev8ntion and Detection is lmeThented by the expected estthishrnentol the new ABC &&)ank which 11 be ¢k)sely linked to the ABC Di%¢over programme. Prevention is focused on improvirKJ our understandiNJ ol the underfying biolog and immunologd m8chanism$ driving lh8 association between diet, li18Sty1è. th breast cancer met&%tasis. This uThJèrstrnding Mll b8tt8r infom our approac to developing nDvel immThJther8pies and rnaximise th8ir therap11¢ efficacy. Detection, invdv8swothing to itl•ntrfy gtycan kn"omarkersthatwill offernov81 t8roets fortherapy. In paraThel, we are continuing our strategy of develoriry novel Her¢epb'n dervatives through the exploitation of antibady engineering. As the projects in the prevention and dÈtection theme develop these vllll into the therapy ttErne. further Inlomiing ourdesKJn approach. Thls strategy alpa1 raveI arbOn to gel ourmost promr6ing therap8UbC molewle into clinlcal trals. We &so to evolve the programme to unite exp8rfMen Immunotheraes th the longterm and ontsrvJ work by ABC on undÈrstanding the impact of Di81 & lrfewe. Where CPPOrfunitps exist to arLalera18 projects, Against Breast Can¢erworks in co118boration with other fiJnding boEAe5. Resulls ofourfunded research projects are pthll$h&l in peer-revieUrna Deta$ otaN publishad paptrs are availaNe frorn the charity WeIle. ACHIEVEMENTS AND PERFORMANCE The TnJslees prowde good govemance by satsguarding and promotiry the organisatK)ns reputation and aclng according to high ethic stsndards. They Ènsure that the charlty acts in a responsible rnanner In accordan¢e with good fundwsing practice. Universty of Soulhamplon ABC Therapelrfie Aniibody Prograrnme201&2028 Ac2dÈm ff: Dr. Charlie Blrts, ABC Lecturer in Antibody Th&rapeubc5. Prof. Steve Beers & Prof. Max Crispin r Sclentisl.. DrJohn Buyer. Poslthctoral fellow and Lab manager T8chnlcal staffr. Anna-kne58 Silber. T8chnlian (Centre for Cancer lrnmunobuyl
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Direclors. Report) (¢¢ntInd) YEAR ENDED 31 DECEMBER 2023 students AB '. Su(k)I, SoB&ABC14th year), Lydia Doherty141h yearl Grace Haye5115t Yearl Tha ABC Therapeutic Antibody Programm8 at Unwersity of Southampton is a 1year pr(pJramTne with a man frKus on developing new theraples. bul the research has significant overfap and synergies across all three ABC pillar$ of research- Prevention. Detection arKI Therapy. The Therapeutic anbbody programme wms lo compl8ment ttE ABC Discover Prograrnm8 and studies on the DietCompLyf BiobaThk upon if$ transferto Soulhampton. Layperson Summary of Proyress The antibody tsam have shown Ihat novel tand8rn Fc rsIonS of Hercaptin lan approv&J 8nti-HER2 anti1y) was b8tt8r atM0r0 bre8St¢xnor¢ellyby Fknagocytrisi51'cellaling'l than an approved dNg ealled margetuximab. Margetuximab iisew IrtOrS better than the or¥Jinal Herceptin so the team are lool¢ing to combine the leare$ of margeluximab th Iheir te Fc Herceplin to further 8nhan¢e rfs breasts cancer features. Tre new atiY molecules have been made and were being tes ia4 20231 in prlinICal MOdS arKI In1b resutts sUgged the tand8m Fc Her¢piin was tÉtter at Controlng turnour growth than singl8 Fc H8rrplin. Building on earfierworkthat hYentied key rfiffer8nc8s in aglycan Iwgarlcalled manry)¥e on trastan¢er cÈILsfrom patientiumours, Iheteam showedtheycan recreatesome ofthese changes in labbreastcancer modds and conduded that high.mannosÈ is a feature ol breast cancer cells that CO[1 be targeted. The antidYtearn designed, prodUd and lesled a novel antibody molecule ttTral targets both HER2 and high mannose thai was identified on breast rAncer cells. The first version was not as etiVe as predthd so further iterations were made and tested whh revealed a successful veOn which is now und8rgolrvJ rther evJualion. Nesy ways to produ{% theTrpeuiic anhbodies at the poim of delwery in Ihe cnnEc have been tested. This approach uses technology c&led Replicon, where the MRNA that codes lor the anbbo(ty is delivered dir8Ctty to the cells. Ral¢On derived Herceptin w4s yoduc8d aThY shown ts be as effeciiva as Stsndard Herceplin. Wotkto understandthe hostirnmune mirmenvironment andthe imp4ctofarfiposltylobesityon ther8peut targetrng and response to therapy has been frvRful. 11 was shown thatditt nLPtrition atrts responses to antlyther9pY Ipaperpublishedl and models lo test the elfect of a hlgh ldietwere comp18ted. Any515 of patient grrAJpstreaiedwith m8ttormin Iwith Drsimon Lord, MaThJPtin progre551. set-upand oplimisation of an Nn Vivo mLN1el is cornplele. CnIc lriaL5 testing m?Uormin in ¢omblnalon SDJdies leJJ. wilh anti-PD-1 antidY1 wll compl&twJ in 6-24 month$l Other Stydies with progres$ in the area ol thÈ'Meta51atic Niche'_ as that bJmur cdls may colon8 In organs distantfrorn the original prnary breast cancer were a5 folows.. Mutromics analysis of metastalic and non-metastaicmurine triplNe9av6 breastean¢ermodel= Proin & tran%riptional andysis was comFl8ted. Cell surface glycan anatys and anbbo target valKlation.' in vitro assay optimEatton Icomplèttrl gtycan any$l5 loryoingl, and ex wvoas52ys16 months). Determinlng the ro of branched glycans in the mÈtrslabc variaffl and their reLqlionshlp to macrophages in the mètsstatic process and pt&metastaJc work in progres$ 1&12 months durabonl. Anlibcdy targeting to metastatlc nlche: set LP and optiM)n of viwo rnodel,. lung metastas Icompletel,. bone mÈiastasis16 rnonlhsl. Set up and oplimisath)n of in vtro aayS IcompletJl, %*fiiLst iniÈgrated tumour mkroÉYwironment and metastase$ 5tuJies are oryTrNJ1648 months duration).
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors, Report) {COnikni YEAR ENDED 31 DECEMBER 2023 EXonre Ihe impactof 0blty0nthe PTfrmetaststlc bone marrow niche.'set up (x)rnaboraon with Iryunn Holen Icompkiel, Optimisation ofexperimenr model longoiNJl. and generalon oftlataforacolLgboiwwe grant application 16 monthsl- N¢w grant Ineome and investment Crispin 15 pwaring a n8w apltiOn to the & Melind8 Gatss Foundatvn that 11 help support the boratory Inlrasinth¢. Therapeuti¢ Antibody Pltsliealitsns 2023 Steve B8ers, ChaAie Birts and PhD Sludent Rhianna Y1h (not ABC Mnd8dl had the foloving paper pui%hed whi¢h complements Ihe ABC programne. BINh RRR, 8irts ¢N. Beers SA. The role of30 in mude15 in modelling the inll&mm8tory mimb7ronment atsoowledwyth obesityinbreastcancw. Breast C8ncerRes. 202325(1)..104. PubhshÈd2028 Sep 11. The follon9 paper5 were published with ABC b8ing nowledged.. B8uer-Srnith H, Sudol ASL, Beers SA, Crlw"n Al. Sewm Immun100 snd the ol Fc r8ceptor. rned12t immune 8ctivation. 8(lM BW Ger) S(. 2023,'1867(IY)..13Q448. doi."lo.tOl&i.bbag2ozj.l3o44& S8W8 C, co E, Johnstrn PWM. cutress Rf, Beers SA. Obesity Is Associeted wylh Immunonyetab Ghanges in Ad¥)trse fissLie Th81 M8y DFNe Tre3tm8nt Resistsn(¥ in 8r88St Cartcw.. Imnne-Me1ats Reprtrgrainmirjg and Novel Thprap8ulic Str8tegles. Cancers {BaselJ. 2023..15(9)2440. Published 2023 Apr 24. doi.'10.3390kartGerst5tr92440 "Prof Cutress is a membpr ofthe ABC Sdentthe Adwsory Board rts CN, MllOrtDC. CouldanionjoLDLtEalig8ndlorFIAGEandTREM2inadti¢n1oLOX./althU$¢¥Cetht0 lung (tsease 8nd denTenb8?BiochMn Wys Acta Alol Basls Dts. 2023.'7869(8).'186887. doi.'10.1016fJ.lybadis2023.16&837 ¢ollHlJor¥tion8 Two member5 of the antibotytèam, PhD stthaeni Grace Hayes Anna-Dese Silber. irisited the Lgb of Profes$¢r Ingunn Holen, Unlversty of Sheff181d in April 2023 to recewe tsning on intracardiaG injections to establish an in Vwti tn(Klel of tone metastasis in Southampton. Another collaboralon has been with Di Sitnon Lord, ABC funded Senior Research Fallow at Ori81 College, Oxford on the wtential use of merfomiin furbreast cancer ABC Discover Programme 2019-2024 A(2demi &kL'. Prof Paul Skpp. Dr. Ban Ncmlas SeniorABC R Staff.. Dr Andrew Shapanls Luis Coy13 yearl PhD Sttjthnts ABC Biobank Progres5 Transfer of the Biobank from the Unety OY W8sts)iinster centinued to be fw5tralingty sbw for Uos and ABC. However, Southampton made key progress in seved parts ofthe prot. Universty of Southampion swnsorship- approved. Data Security and Protection Toolknt application to NHS Digtal-approved B85 Secure Data Centre- commissioned D*a Protecth)n Intern Asse$5ment IData Risk assessmert)-8pwoved IBAS IlntegraiÉd Research ApicatiOn System) subrnission-approv
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT {In¢orporating Ihe Directors, Report) (CL11¢ YEAR ENDED 31 DECEMBER 2023 CAG Iconfidenliafity AdvTsory Group) 5ubrni&8lon-proved Material trarn8fer agreement b&een Uos and Univ?Nty Coll¢g• Hospit8t-approved Collatx)rative agre&rnt between Uos and Unwersty of Wesbminster-approv I spac8 converted and reatyto retewe biobank. mmplete Addition steps required forthe transferofthe Biobanktouos ar8inprogressandare largdydeKndt0n actions bythe Unlversity of Westminster. ABC Dlseov Research Progress 2023 Mr Lui$ Coy, ABC Funded PhD sludent Further Imiestigabons were condCle into the utra4ow adherent IULAI Cell culre model of Iripl8-negabve breast ¢ancer (fNBCI. This m¢Kld is s¥Jnificani as itdisplays rnorecllniralty meaninglul charaen$t1¢s than tradthonJ 2D cutture systerns. The ULA SD model of Caer cell spheroids was studied using the triple negative breast cancer cell line. MDA-M&231 and cornpa tothe standard 2D model- protein anaTrJsuq bthveen Ihe tsvo mthyels showed dlstinct differences whSch be linked to key canr cell svJnallino pathway5. Protein anYs1$ perfomed and completed and gene expression analysis ha8 been initiated,. earfy resuyts again show key drfFeren¢e5 whK highlight that 3D spheroid mcdds of f2ncerolls are more representative of tumours in Patients. Luis preserrted his wortattt)e BSPR-EUPA 2023 (Biitssh knetyfor Prot¢otne Research and EurokEan Protsome OrganiZati() I nferenc9 held in Newcasue. Dr Be# Nlchola4 Personallsed vacclne development method Dr Nicholas ha5 been develoFing an in-wtro rner Sn which the Controll enQuent of dying tumour relLB (triple negative breast cancarl can be used to idantity tsrgets to promote antptumour cell mediated irnmunty, irtilisinu a method cled 1mmuTr)ptid0mlts. Thi5 highly advanced rnethod ams to reveal Sm1 p8Ptides unique to tumour cells (beCaSe they contain Ntutationsl that represent newtsrgets fOrperEonaKS vauxne development Dr Andrew Shapani5. multt-cancer early detection tesi In 2023 Drshapanisand Prof Sknpphave conllnued dÈvelopmentolth8promi*ing Mutt68Yc8ncerdetection test IONCO-DX is a test being developed to lOW early detection of up lo 12-cancers, induding breast can(Er from only a pin-prid¢ of blood. miONCtsDX measures small RNA fragments in th8 blood rnicro-ANAs ImiRNAI. Head 10 head studies With i)ther earty cancer detection te8ts havÈ indicated that miONGCkDX has supofior sensitivity and speBificty, in parttcular for the delecuon 8arty stage l and 11 canr5. Dr Shapanis has bpen in dk8cussions with potenti parknersto cary outthe feawbilty and development ofthe iesL miONCOwas pltched at the FUre Worfds Demoday aithe Lon(bnT8ch WaeklJun&20231 and il r8c8ived signffjcant interestfrom experts wtentid Investor& Plans lor a dinif21 validation lrial of the miONCO18St are und8nYay. ABC Dtscover publi¢8tlorts 2023 Nicholas B, SklppP. Whaldo canr.$pC CD8+ TSee? Th8conlnbubon ofifftmunopeptrdonwts. Essa BiochÈm. 21723,.6716).'957.965. doi."10.104aE8C20220246 Uos Engagernent with ABC ABC held the first ever Breast Wth Ev8r8vent In Hampshire in May 2023. Mary ofthe ABC furKled rEsearchers. their paTtrell arKI other lab membets all volunteered for marshalling duties. As well as raing funds lover £16.0001 there was highty positNe leedbadt from parbopants Citing how wonderful ft was to See th8 Uos researchets and Professors on the route getbng Invofved arKJ have the chance to ¢hat with thern. First year PhD student Grace Hayes was featu in ABC's'lnvesting in women in STEM and breast cancer research, artide. Thi8 can be read here.. ncer.o .uklre 8wsAnvesiin
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Dlrectors, Report) (L0 YEAR ENDED 31 DECEMBER 2023 VnNer5ty of Southanplw ABC Open Day I110bar 20231 Southampton hosted anABC cpÈndayatlhe Highfi¢ Camws. TrABC fuThJed researthersgaVetksdesCnig resear¢h progress. ABQ staff. ABC cfrlounder Patricia LeathÈm, Sports Athctate Dr Karen Am8y and a number of supporters and volunte8rs attended. Ml We treated to exlIent talks, a fascinating lab tour and 9d ¢Jiscussions With research team over lu. University of Oxford, Orid C4)IIEge ABC Orl81 College Fellowshlp Programme 2018-2 C Seni Fellow.. Dr Simon Lord Dr Lord is a SÈniar Clinical Researcher in ExrIMe Cancer Ther8Pr¢S based in the Early Phase Cancer Tri5 Unit and s0 a ¢on5uttant medic31 oncologist at the Oxford Cancer Centre. Dr Lord continue5 his wo investigating Iherapeutic approacFEs to targ81 mitotthondria and definetl two types of metabolic resportse to the diabetes drug, meifoTmin. in breast trancer. Mefforrnin is a widdy used di2betÉs drw that has sh¢)wn prornkge as an anti-rancer agent. HowÈver, Some clin1c trial results have been innClusrrfe. Dr Lord asks the question in an April 2023 publi¢ation tided 'ls it Still worth pursuing Ihe repurposing of metforrnin as a cancer therap8utic?' His ewint is thattril desvjn has otten been su&oWmal when inveslrgating the eflects of melfortnin, so il warrants lurtherdini¢al in $elee popJlalions With better assessment ofwffttAnallons wth othertrem8nts such as irnrnunolher8py. A Clinic in llaboratIon wth UnnieitY of Souihampton is ongoing te5bng the effect of metFomin. Dr Slmon Lord Publlcatlons 2023 acknowledglng ABC Coombes, R. Q., Ho1/, S., Lord, S 8., Kenny, L, Mansi......Krebs, M. G. f2023). Dtrseesr&tion andÈxpansi horts in patients 8dv8nced b51 C8ncer in a Phas& I study of the GDK74nhithior $afflursllb. N8re coMmun20n$, 1411), 4444. hUpsJ/d.l0.lOs8l54I4G7-O2s4oO81-Y PagnaT8nts. A T., Camp4 C., Gia¢opuzzi, E.. T8fvr, J. M.. Hashim, M.. Calp8ni E.. Katsaki, P. J.. Hashfrmoro. A., Yu, J., Sanders, S., Lord, S. R, Hughes, J. R., Vavoulls, D. V.. Allrogg8n, H., ... Tafvr. J. C. (2023). Struclural and non-&Wil wT8nts inGrease the di8giyostiG yield of chnical Lthole genome 58qU8nc4ng for rare thsp8ses Genorne rnerf, f5(lJ, 94. h 073-D2 Lord. & R.. & H8rns. A. L (20231. Is it woth ptstsumg Ihe repuyng of melformin a& a c8J7cer therap8utsG? Britishioum81ofc8n¢er, 12816), 958-966. hltsJ/doi.oWO.10gWs41416.02&02204.2 ABC Junior R search Felbsv.. Dr iina Hacker Dr Hacker becamè the new ABC JunK)r Research Felk)w in Aug 2023 p8rforrniry research ai the Deparment ol Oncology, Universityefoxford. naCOmPted PhD in M8dital Suences atlhe Univer5ty of caMge, where she worked on ihe bKil(gic and tthnical valldation of photoacoustic imaging blornatr5 in breast cancer. The Against Breast CartÈr Junior Re88arch Fellowship sJpp)rts her wofft on developir¥J new imaging tools and strat8g18Sto deQtand8tratityhYpOX1aleVe151n brewrAncer. Th?airn ts ID deteCtaggreyÉ tymourtypes ewlior, ch005e better treatments and develop bett8r ther8pies to Lyjmbat breast Canr. Barts Cancer InsWtutelQue¢n Mary Unlvelsrty ded PhD Prwanka Hirani Priyanka Hirani lrnw Dr Hiranilconbnued andcoMo Irat8 20231 h8r PhD studies In the lab of Dr1Ver Pear. who previously recewed an A8C seetl grant Priyanka is studying the lumour Mr0envirOnmenth her r8search 1$ fDcusseLf on how to improve irnrnunolhewy response lor trie negatwe breast canor patients. Dr Hirani has been inveslKJabng the role ol thè protein Ver$an in excludirg the a¢ce55 of cancer-killing immune ¢ells reaching tumour cells. Dr Priyank Hlranl Publl¢atlon 2023 acknowledging ABC
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporaling the Dlre¢tors' Report) fL>)nllnu YEAR ENDED 31 DECEMBER 2023 E. H.. Tfvr, E. J.. PÉérani, E., Hlranl, P.. Gaubw. V.. Y.. Maniscalco, G., Rajeeve, V.. Ctsblks. P., TvISan, C., P02zoixJn. M., Lodrley, M., Rastrid(, J., Whrfe, A.. & Pearce, O. M. T. (2023). EktraC}ular&til¥ irnrnuntrwts12torylufftorm8whagephenotyp8 foundin ovari8n C8nCÈrMpts5t55. N8Èu cornmuni¢ation& 14{1?, 2514. h 10. lQ381s41 .023-$8093.5 n.b brst cancer manu5crFts in preparation Dr Hirani a150 featured In ABC's'lnvestiro In women in STEM and breast cancer researth, arde. .uklr -newsfinveslin -in-women-in- d•reasi-t Charty report 20¥J brougm with it the very first of Breast Wk Ever Hampshire. Tthng place just Oude of Wirthesrer (dose lo where a significant part of th8 researth takes ace at the Universty of Sothhamptonl, each route gave panoramic views of Winchester and its wonderfully undulating surrounds from various Natn81 Trails. Hugethanks to the research team at the UnivÈtsity of Soulhampton for attending on the day and who helped in parbcular participant and volunteer wruitm8nt. Over £21,000 was rais8d from the event. Ourswrts Ambassador Karen supported us with the planning of Bastwalk Ever Hampshire and 8ven IDund lime to puttogelher a ¢ouple of blog posts to h8lp inspire people rerrfing Ireaknent to get regular exero5e. Th8se ar6 both avalable on the ch8Yty wèbsite. Karen s0 hosted her very own 10K walklrun ev1 in her vilLgg8 of West Wellow. attracting over 80 parbcipants. In February w? expanded the Events team recruillng a S&C FundraKr In line th our 8tr8tegy to grow this income strÈatn lo MlmuM potenti. Income for events saw a healthy growth In 2023 surpasslng the • Set lor the year., We hav& supported 208 S&C fundraisers who have rased an avtrage of£1298 8a¢h Top 5 events in term5 01 funds raised London Marathon.. £5U85 2. Breast Wall( Ever. induding sign up lee5, merchandise aNI fundrasing for Wh walks.. £3354. 3. Berlin MaratfKJn'. F29.fJO.LXJ London 10 Paris bike rid8'. £17,810 5. London Trihlon.' £9,564 In September, Ihe Oxfordshire Breasi Wajk Ever suitabty brought Ih? surwslul 2023 events season to a dose ilh yel arniher great day offundralg n our tommunAy. 2024 London Marathon 2024 2024 yrill be the first year that our radwed allocation of Golrlen Bond places comes into effect We have just 12 places rather than the 20 we have enjoyed in recent years. Excdlent stewardship will be VI in fflaKimBlng fundraising. Berlln Marathon 2024 Berfln Marathon will be CebratIng it'$ 50 annwersary in 2024 and demand hay never b8en higher. We have 28 runners and are forecasting to be awe lo breakthe £30k mavrt in temis of fundraising next year. Berlin is one of the 6 Abbott's World Marathon majors. Something we are looknng to focu5 on in 2024 as we seek to maximise fundraising potentiJ from those at home and abroad who Covert the highly sought after'6 star finisher mExlaV Breast Walk Ever2024 Both 24 walks are now live and on the WebSe 2nd open for sign-ups. WÈ are trialling a new online frJndrasing plattorrn next year called iRai4er. The re attraCtn 1$ thaL fur&S[n9 page creation is made mandatory c*Jring the sign-up fN)w. We hope this will tranale to a greater percentage ol parbcipanls part in frJThJraising.
AGAINST BREAST CANCER LIMITED COMPANY LIMrrED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors, Report) Ic0Jnue YEAR ENDED 31 DECEMBER 2023 Viri101 fundralsl We klan lo plloi a CDuple of rtu fundraEiro campawJns in the newyear including Take 30 wheTr supporters are inviied to parbcipantand lundwsewia Facebook. Weare s0 atconlacung agroup of10c SuppOrtewhO are expprienced gamer$ to see how they can help us to champion gamInStreamlng fundraising In 2024. SeM-$uffidenry Work is continuing in thÈ exploration ol gramty foms and an integration Stripe. This would allow us to take event sign-up fees and sell merchandise via our website Y4ithout needing to use a third paty. The supporterwould also be atAe to set up a fundrwsing page and aulDtnabCIY be put on to a bespoke em1 jwrney from tr point ol engagement. Community fundrdising Community fundrwsing continued ai pacelhroughoui 2023 with lots of SPÈCfdl highlNJhts-. Oxpink Week took place the last week of January. Our Chwr ofTnJstees, Rithard 8ahu atteThJed Ihe b&1 which raised a larnastic total ol £13,968.00. £5.222.20 was (kjnaied to Agalnst Bre Cancer Bagoy Bras Put on a show in April that sold out, they dvj a greatjob wth Iheir bra donations at 8ach show. They so helped in raising awareness by ryrcuL3ting our leafiets atall of Ih8ir shows. They raI88d £915.00 Splash Of Pink Splash of lir1( retumed to Abingdon Markelplace in July. As well as a lot of Ihe okl lavourftes rftthng a rern (storm troopers, Fiona's Cakes, Ro(l( choirto name a fèw) as well as local s&ii hOerS Kar8n Hockey, the Ladie8 Captn at Nuneaton Golf Club selected Ag&n5t Breast Cancer ftsr the club's 2023 fundraising, culminab"TrJ in their annual 9olf day on 1 of Septetnbpr. Karen came to the office in AbingdDn for a cquepresentat.0n inearly2024. Karen has also acceptedan inviteto n8xtyea¢s Eabtouratorfel College, lknrd. In to Karen and her team raised awonderful £5,235.27 Sarah Defern continued her unbeliavatAe fvndraising efforts for Against 8reast Cancer in 2023. In amongst a number of Èvents this year, Sarah wsed a SnnIng £5.653.46 in December by hokliNJ her annual Santa's grotto 8venL Sarah herlamily have now raed in total. the phenomenal arnount of £85,661.97. Rob & Shirtey McBrldeatso conlnue Iheirfabulous fUTKIraan10urneyvMIh afestive theme. Togetherthey ratsed £3,040.00 in December by holding their annual event of rnaking and seNing Christmas wreaths. Their total to date Is jusi over £15.0(M) Charity Angelsorganised ifashion showon 12 CktcthrvrtTrere am the mojels have haddirect ?xFerien¢eof brea81 cancer.Jusi over £3000 was rSed on a brilliant nigm OffUraIn9. 8ucks Buxom Belle5de8igned, m(dIed and priniÈd calendarswhich were SO to raise moneyforABC and one Other charity. NJI the mde15 in tre calendar haveAYenl through breast cancer. They ra1% an astounding £2,000 for ABC. 224 Goti Lynne & Steve Bray (husband and wlel aub and Laty Captain ao keeping Ihe goll therne going into 224 at Sandford Spring5 GOW Club. They have started fundrai&rvJ alreaty th plan8 lo raise in excess of £10,000 Ihmughout 2024. Splash ol Pink 2024 S8veral nèw acts 11 join us in 2024. The ertOneS will lead the billing wilh an hwr set. The ffrst bme wo have had a "Headline band.. We have secured a furfher £500 sponsotship from eur new tharity parkner Seleth¢ RlUianU with the usual £500 gratefully receNed onf again from Slade legal. Pub8 In Plnk To compliment our Play it Pirk eampaign, plans are in to go after Duded sporting aTrtieS such darts. 5thes and cribbage by contaciing pubs th communty group5
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the DireOr$. Report) l¢onth YEAR ENDED 31 DECEMBER 2023 R8ts11 E-Comm¢r¢o Spring broughtabouta$ignificant increase of interestin oursumNEr5portSWEarparbcularfythe wdingjerseys and running vests. WehaveexpIor newlinesolsportswearlproductswhich have been putlogetherto makeournew'bundle, options. These are grj lo be a way for wstom8rs to get a number of reant products for their Èvenl in one go, for e $IhY reLluced COSL We are expetting them to be wpulararKI h¢pe for incyeasedsales, while Jsoselling Ihrowh some of our51ower sdling lines. MerChande such as pin badges Contin to be very wwLarwith our$wpDrters. Revarnp ol the Big Cornmerce shop. The user inl8rface is lOoj more o¥namic arKJ tolwrtul wlh stafF modelling the 5POrtSW8ar. Both numb8rolv<s and nuinber ofcustomers are up in tenrs ofthe online shop. Visils up by38% Ih 23,902 up from 17,330 for the s8rn8tSm8 last yew. Custom8rs up 25¥ Imlh 275 Alherthan 219 forth8 samè pÈriod last y8ar. Recycling The Recyding Department has seen a drop in income from trE doorstep textile recyclino over the last few yearsSupKx)rter5 tend to hold on io their dothing longer du8 te ojst of living and this learts io a reduction in the qUlty of textiles donated. During 2023 we rètenfed and responded tt) complant in October 2023 and no further wntact has been recewed. Bra r8(ryding continues lo bè a powL7r was for supporters to fundrai88 as t&hnically thu8 is a f Wdy ItheM lo se fUS for the ch81ity, as they do rni need to SP8nd money, just donat8 their unwaffjed bras. Our bra bank scheme is very popular with companies such as lingerie shops, supermarflets eic. We a&0 have 2 radio stabons that hold an annu& bra recycfing events0 that notonly brings in Ihe bras for ¢¥ClIng buta0 promote5 the chanty and its mission. Stamp recydiro dwbled its inwme from 2022to 2023 and i%stiii very popularas not many charities collectstarnps now lor recycling. Cartridg8 ty¢ling took a reduction in linance in 2023. this is rnainly due to %vhi¢h cartridge&fan be retycled, these change fUentty deppnding on the legislation for r8cycFirvJ cartridge5. Digitrl and Development Our inveslmeni In tleveloping the digit 5kn11s ol staff has contributed towards ourdatabase of supporte[5 growing by ov8r 20% tr)i5 year. By ini8grating our systems we have ensu they recenie the tÉst expsrieTre possib. These measures combined lo help us to imFme and tetter manage Dur communications. Saving valuable time and resource. By collecting paticipant feedback through the use of surveys ènd questionnares. we plan to use th8 feedba¢to continue to improve the supporter axperiertce. We continued to irnkyove website. giving SitorS confidence that the page5 ar& up to date and refled JIren1 knowlEdge. We now havethe facilty to a¢p1 donations from mobile devices using Google and Appw pay. Staff haveattended nurnerousevenisto LWerUndersdthe impact arkfici intelligence might have onthecharity sector. Unlocking such wtenbal wll nSIder btsth the ethics and the% newtechnologies present. Follong Ihe SLwssful linknng of our onllwd shop wth our emal software. we have been able to signrfwly improve the targeting of our matheting mmuniCatiOns. Digital dashbDards have b8en dasigned giwng lundra88rs abetter uThJerstanding of howpeO8 ar8 enpagirvJ the charty and which events or messages are resonating supporters. All told,we expectthese measures to 10 us to mÈel the hyjherdemands expected to be gn statt overlhe comiry years. A successful apF4ication mad8 eatly in the yeartothe Medical Research Cwnclls C4vid Medicèj Aasearch Charity Support Fund reEutted in an award teing rnade In excess of £175,000.
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors. Report) (¢otttthuedJ YEAR ENDED 31 DECEMBER 2023 FUndraIng from both malings 8Tr1 Trusts and Foundatv)n$ performed weN this yÈar. Improved segmontiOn and targeting ¢ombined lo delwèr Strong re5uhs which we plan to lurth8r develop ne¥lyear. The Smee & Ford Legacy Nolffjcat"on Servieeto which were¢entlysub5crbed geneAtÈd Tnup1egffts from estate$ where the leyator had left fvnds to charity. These generous individuals were not prpviously known to the charty. we are plÈ4sed that our applications have been so well received. To this efFecl, we have srarted a review ol our Legaoy l Grfts in Wills ft1ndo1ng strategy. We have $0 recognised the importance ol hawng a Legacy Manager to handle these gifts. We have appointed an eXtiNg rnemr of stsff to fu1 this rolè and have made provision for them lo re¢ee appropnate tmning. FINANCIAL REVIEW Aganst Breast Canc8r made a bs5 of 1£63.2081 in 2023 compared to a profft of £17,552 in 2022. Consolidated income for 2023 %vas £1,110.053 compared to £875.116 in 2022.Thi5 demonstrated a tnarked increase in furKIs indicatingthatY4eare enteTrro intoamorestable riod. As we rnove into 2024there is adefiniteuplift in fundraising wNh events now back lo almost a pre paThJemic levd. Edging closer lo bringing us back in line with the 5-year in¢omegrovrth strategy of 2019 with th8 intention of irueasiTrJ irKX)me to£1.5 million overthp nextwuple of years. Following the funded research of th8 DietcoMp stuty at the Lhniersity ol Westminster in 2015 the charity developed a research strategy funding long lenn and $hort-term innovative research projects. In addition to our long core research we aLs0 fund PhD's ar Junior Research Fpllowships for the advancemerrt ol UC810n through leaching and research. These projects are funded restM)nsibly in line th Agwnst Breast CÈnors objectives, and sUlUS funds riw fend annually for further spend on research projects and lab Èquipnent. Th8 research strategy and charity long term projeGtions see resp)nsiNe, suslainabie and Substanti growth In tUrlj in line wrth wojÈsted growth In incornp and maximising ROI. Aganst Bast Cancer rxjntinues to work wrth the clinical sponsor of the Die1CompL sbJdy, Universty College London, to wl proces5 in pla lo make the data and sample$ frorn the Di8tCompLyf available lor futhr research. Aganst Breast Cancer has a projected long-tem research portfollo in exo5s of £4mllllon. Tris PDrtfolio has en steadily built in line wtth the research strategy andcharity long term projections ensuring sustainabilityfor the fUre. PLANS FOR FIMJRE PERIODS Plans are in place to rtwimi8e potential of our online plattorm funcbon. We have exped Ihls team with the r8cruiiment of an Online Platrom) Assistant. A campargn to increase end ol line 5toth donations frorn coryy)rates and small businesses to sell on Ebay and other online platforms is bng Put in place. By popular dernand wa are bringing back a couple of old merchandise favourite5 in 2024 too. Firsity, the dassic pink pin badge that was desNJned bysame person whodesigned Olympictorch in 2012. Additionally. r8siocking the2018 Pinkrlbbonbaulle Chriskna8 card that prov immensely popularas as designing a brand newcard for Christmas 2024. REGULATORY COMPUANCE Trusteeseonbnueto playan a¢bve rok in theadministration oflhechartiy, ensuringweare aceouniableto everyone th an intsrest. They ensure th8 tharity's reUrCeS are managed resF¥)nsibly and in acCOrdae Wlh rrent legislalon. The truÈes abd8 by both the Code of Fundraising Practice and the Charity Govemance Code lo ensure best p9Ible practice in Iheir govemanca ol Gharity. STrUCTURE, GOVERNANCE AND MANAGEMEI Govemlng Documerrt Against Breast Carter tirrwled 15 a CpanY limited by pjarantee and registered as a d)arity. The goveming document ol the charity is the Memorandum and Articles of A8sociation issued 11 Juty 2007. Governing Boty (knrall respDngbilty rests With the Board of Trustees who aTe $0 aFpolnted as directors of the charflthtt company. Authority from the Trust888 is delegated to th8 Chiel Executwe ICEOI, Bemadette Jones, who is T8sponsitAe lor the ¢Jayto day managemerrt ofthe charity's attats and forlhe implementation of policies agreed bythe board. Th8 CEO i8 assi%ted by a management team. stafl and volunteers. The board approves the delegation of fina atrthorty through the CEO, wth specific limits imposed Mlhin an arproved stherne of ddegation. 10
AGAINST BREAST CANCER LIMITED COMPANY LIMrrED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Direclors. Report) (¢OJJllhued) YEAR ENDED 31 DECEMBER 2023 R8¢tuiknert AppoinknenL and Trainlng ofTrttStres The aM)ointrnent of frustees is mad? in accordan¢e wth the deS ol AssocL4Uoft which indL&lesthe receipt and approval of an application for membtrship. The sel8ciKJn of Trustees Is designed to supplement the existing $IL# expertisÈ of the Board and is govern by an informal sknlls assessmÈnt. The Trustees ocognise that a more forrnal approach should be taken in respeci of their inductlon and training. paticularfy as regards to new appointments. and procedures are beirvJ formulated this year. This includes th8 declaration of eligbiltyto serve a Trustee including notrficabon ol any potenti conflicts of interest. Curr8nUy Agwnst 8reast Cancer knmiled has eight Iruslees. Together they provide a broad range of sknIIs 8nd experbse that the trustees Wdnt represented to ensure a strorg board - these include sciènbfic and m&11C backgrounds, sirategic thinking, financial and 0ry8nisabonal managtment and marketing skn115. In addltion, many ol the tnle$ have person experien ol the Impact of breast cancer on peoplès, Iwes and so ar& empathetictowards the god of the charity. OrganisallohHI Alanagement The Ini$tees have gaI responsiblity for the strategic dlr6ction and effectiv8 governance of the charty. The trustees. also being directrors ofthe companyb who 88rv8d (ljrfng 2023 are Il$ted on page 12. on avewethe bowd meets four titne5 a year. Group Structure and RElatronships The Charity has awholty Own sub$18ry, Against BreaStCarer ral) M, regisl8r8d in England number 6310215. The subsidiary operates from premises aged by the charitable wmpany and sells promotional items bearing the Against Breast Cancer logo. It donates its taxthe profits to the charitable oompany. Against Breast Cancerachieves its objective of mmmissioning research through its close relationship wlh a research team based at UnNersity of SoLrtharnpton. and a earCtt team based atthe University ol Oxford. Tre charity provides a grant to each team which funds their sdary and laboratory eosts and enables ttE ongoing research to tske place. Agart Bat Cancer also established a F811owship programme in 2014. to supwrt rising scientific tent in the breast cancer research field. The first 3-year Fellowship is associatedwth Oriel Gollege. oxy0, and was awarded to Dr. Ma% Crispin who is des¥Jning newtrealmentsforrneta5tabcbrea8tcancer. Followir@ on from Ihi5 Fellowshrp. in 2018 Agnst Breast Cancer 1 Oriel College sÈt up a 9 year ABG funded Junior Fdlowship yogramme to continue advancements ol Èducation through teathing and re8ear¢h. Reserves Policy Agn$t Br8a8t Canr deaded on a policy of holdlNJ 3 to 6 months 0rating costs. A figts of £150,000 was considered to be a reanable lÈvd of reserves lo bp he that would enable the chadty to meet JI of its liabilthes should operations have to cease al some point in the fubjre. Thi5 include8 dl ¢osts such as re(hJndancy lor employees, professional fees and awind dovm ol the iesearch prograrnme. As 31st Decernr 2023 the charity hd total reserves 01 £353,989, of IhL8 amount £10.000 was held as restricted. Rlsk Managernent The maior risk8, to which the charity is exposed. as lentified by the Tmses, have en reviÈwed and SemS have been 8Stabltshed to mthgate those risks. REFERENCE AND ADMINISTRATIVE DETAILS Rtgistored charlty naffl8 Agwr6t Breast Canw knmited Charfty registratlon Nmber 1121258 Company reglstration number 6310215 Reglstsrad offie* Lealhem House 13 Napier Court Barton Lan? Abingdon Oxon OX14 3
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporallng the Direclors. Report) (conth YEAR ENDED 31 DECEMBER 2023 Tha trustees Tho tnslees who seNed th8 charity durfng the were as lollows.. MtsJ Chattoe Mis5 V Hamer Miss N A L WetrA) Mr R Bahu Mrs L Hounam Mrs J Collins Mr D RemouThYas Audilor Xeinadin Audit Limited Chartered Accountants & Stslulory Au(blor 88d<ett HoLe 36 Old Jewry London EC2A 8DD AuDrroR Xeinadin A11 Limited are deemed to be re-aprM)inted under sectron 487121 of the Companies Act2006. 7RU5TEES' RESPONSIBIUTIES STATEIIEiir The truste Iwho are 50 Ihe directors of Against Brvast Cancer knmited for Ihe purpose5 of company lawl are responsible lor preparing the Tnjstees Annual Report and the financi stetnents in aco)rdarte with applicabje law and regulatb?r. Company law requires the tnjstees to prepare ffnanciJ statements for 8ad) financiJ year. Under Ihat law the trustees have e18Cted to prepare the financial statements in arxordanct Y4ith United Kty)gdom GenerlY Accepted Accounting Practe IUnile(l Kingdom AccountiTVJ Standards and applicable lawl- Undercompany L8w th?tlUSlee5 must not approve the financial stai8menis unless they are satisfied that they gwe a true and fair wew of the state of aftaits of the tharity and the irtix)me and expenditurÈ of the chaiity lor that perd. In preparing these financial statements, the trustees are requiredlo.. select surtabl? aCCWng policies thèn apptythem cortsistenYy- obs8rve ttTe methods and principle5 in the Ch&ities SORP.. make judgernents and accounting estimates thatare reasonable and pwdent.. and prepare the financia statements on the goiry concom basis unless it Is Inwropriate to prastsme Ihat the ¢harity will continue in opetalion. The INstees are responsie for keeplng aderwate acLounUng re¢ords that are su1cnt to Show and 8xpLain thè chanty's trartsactions and disdos8 with reasonable accuracy ai any bffle the financial position d the tharity and enable Ihemto ensurethatlhefinaNad stalementscomplywiththecornpaniesAct2006. They arealso respon&blB for Safarding the assets ol the Charity and hence for tthng reasonabl8 Steps for the preventbn and deteotion of fraud and olher irregukrthe sTATEmEP AS TO DISCLOSURE OF INFORMATION TO THE AUEqTOR Each ofth? persons who i% a trustee atthe date ol approval ofthis reportcortfirrrtsthat.. so faras each trustee i% aware, thereis no relevantau¢ltinfornatlon ofwhitththe th3rty's au(fftorls unadre-, 12
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporaling the Directors, Report) rconv) YEAR ENDED 31 DECEMBER 2023 each trustee has taken 1 steps that they ought to hav8 taken as a inJstee to make Ihems8lf awaré of any relevant audit infomwtion and lo eStablh Ihat the charty's auditor is aware of ttw V0rrnaOn. SMALL COMPANY PROVISIONS Th[5 report has been prepared in actor(knce wlh th8 pmmsions appllcable b ty)mp8nies ate to the smdl cornpanies exemption. Registered office.. Leathem House 13 Napier Court Barton Lane Abing¢bn Oxon OX143 Signed by order ofthe bu8tees R Bahu Trustee DIrtsr Septemter 2024 1S
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF AGAINST BREAST CANCER GROUP LIMITED YEAR ENDED 31 DECEMBER 2023 OPINION We have audit lh?finand statements ol Agwnst 8reast Cancer Mited ltt)&'ParentCharlke Company'l aTh rts subsidiaries Ithe'Group'l for the year ended 31 Dec8mb8r 2023 on page$ 17 to 31 which comprise the Group Staiemeniof Financi ACtlie5. th8 Group Sumrrw Infx)me and Expendilure Awourn, th8 Group and Ihe Parerrt Charitable Company BJance Sh8et, thÈ Group arKI the Parent Charitable Company Gash Flow Stalernenl and laled note5, including a summary of significant accounting poli88. The finantial [¥)rbng framework that has been applied in iheir prepdrabon is applicable law Unite4 ngdoM Accounting Standards Iunitèj Kingdom Gen&ralty Accepted Accounting Practice) induding FFIS 102"The Financial R8p)rbng Standard apI¢2b1É in Ihe UK and Republic of IreL8TrJ" In otsropinion= the tinancial statements gwe a tme and VEW of the stat8 of the Group's and Parent Charitat48 Corrpanws as * 31 Dember 2023 and of the Group's and Parent Charity's incoming resoutus and application of resources, indLbJing As incomÈ and expenditure, lor the year then ended., the financi statements have en prop8ty prepared Sn arwrdance with Kingc>)m GenerlY Accept Practic8", the finanaal statements have been prepared in accordance with the Companies Act 2006. and the Chaiitvds Act 2011,. BASIS FOR OPINION W8 condu¢ted our audit in accordance with IntematEonal SlandaTds on Audthng IUKJ (1s (UK)) and applicable law. Ourresponsibilities undertho% StaardS are lurthef debed in the Auditorfs responsibHities forthe auditof the financial atements section of our report. We are independent ofthe group and parern charitable company in accordance the ethical requirements that are relevant to our audit of the finanual statements in the UK, induding the FRC'S Ethul Standard, and we have fulfilled our other ethic PDsibIlItieS in accordance vAth these requirements. We believe that the audit evenCe we have Dbtaned sulficienl and appropriate to prowdp basis forour opinion. CONCLUSIONS RELATING TO GOING CONCERN In aud. the fiTTarod statements, we have Gonduded that the trustees, e of wing concern basB of acwunting in the pr8paration of the financial statements is appropriate. B88ed on the work we have perfomed. we have not bjentified any material uncèrtanties reL4ling to 8vents or tx)nditions that. I*UallY or collectivety, may cast significant doubt on the Group'5 or Parent Charitabie Companys ability 10 continue a5 a going concern for a period of at least months from whèn thè finanri slaternents are authoiisedfor issue. Our Tesponsibilthes and the respon&bilities of the trv51ee5 Wth resp to going are descrbi ed In tho rdevant sections of Ihi% rewJrL OTHER INFORMATION The other infomiafjon comprises tho infornation indLk1ed In the trustees, annual repJrL other than the finanL¥ statements and our audrtor's report thereon. The trJstees are responsible for the other information contained within the annud rewrL Ouropinion on the financi staiernenis does notcoverth2 other information and. exc8Pt lo the extent otheNlse eXplicY stated in our rekh)rt, we do not eX8S 8ny fomi of assurarKe conclusion thereon. In wnnection wlh our audit of the financi statements. our responsibility is lo read the other information and, in doing so, consider whether the other information is rnatenIY inconsistent wrfh the finwKial statents or our knowlèdge obtained in the audit or otherwise &eats to be rnaterially rnisstated. 11 we identity such materi inconsistencies or appartrnt mi55tatements, vle are rewired to detemine whether Ih8re 15 a materi misstatement in the finanual SlalenEnts or a rnaterial mKsstat8menl of ts Other information.11, based on the work we have performed. we conclude that there is a material mstateMent of this other inlormation,- we are required 10 reportthat lacL We have nothing to r8PJrt in this regard. 14
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF AGAINST BREAST CANCER GROUP LIMITED (con1thth7d) YEAR ENDED 31 DECEMBER 2023 OPINION ON OTHER MArrER PRESCRIBED BY THE COMPANIES ACT 2006 In our opinK)n based on the work und8rkken in the course ofthe audit.. the inlomiation gNen In the Tru5te8s Annud Report arthrporabng the dSrwrs' report) for the finanryd year forwhich the finanti statements are prepared Is CA)n$6tentwith Iha finartial stalernents the directors. report has been prepared in aOrdanCe appiicable le9 ru1rern8nts. MAThERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION In thè light of our knowledg8 and understanthng of th8 Group and Parent Gharitable Company and its environment obtained in the fX)urse ol the audiL we have not k1enbfied material misstalemenls in Ihe directors. report. We have ry)Ihirg to rewrt in respectoflhe folln9 matter5 where the C4)mpanie3 Act 2006 and the Charibes Act 2011 rewires usto rewrtto you rf, in our opinion.. Th8 Parent Charitable Company has notkept adequate arKI suTficienl aOUnting records, OrrurnS adeqLWte for ouraudit have not been receDied from branches not ¥Iled by us.. or The Parent Charitthe Cornpany firAnco1 statements are not in agreement ytr Ihe accounting recerds and retums.. or Certan digd05ure8 of dIor$. remurratK)n 5wfied by lasy are not made.. or We have not recepied all the infomiation and explanations we requirè for wr audlL or The Trustees were not lo prepare the financ1 skternents in accordance wth the sm&1 CoMpanS regime and take advantage of the small companies exempt'on from trTe requirement lo prepare a directors, report and Strategic report RESPONSIBILITIES OF TRUSTEES As explained more fully in the Iruste8s' reslbes ement Iset Otsl on page 121, the trustees (who are aLs0 th&directorsolihe Parentchariiable CompanyforihÈ putPOSes of company lawl are responsiefQrthÈpreparaI10n of the financial statements and lor bping saisfied that they give a true and fair wew, and for sud) intemal control as the trustees deterrnine is necessaryto anaethe prep8ratiDn offinanaal statements that are free from materfal rni&siaiement, whether duelolraud or error. In weparSngthe financi statemÈnts, the tNstees are reSpor1b forasSeIngIhe Coup's and ParÈrrt CharRabl8 Company's ability to wntiftuÈ a5 a going corttm. disclosing, as applble, mÈtters related to lg concem arKJ using the going COnM basis of accounting unless the trustees either intend lo liquidate th8 Group or the Parent Charitable Company OTto ceas8 op?rations, or have no reIStiC ternative bJt iodo so. AuD0B's RESPONSIBILMES FOR ThE AUD OF THE FINANCIAL STATEMEKrs We have been appointed as auditor under section 151 Charities Au2011 and Uerthe Companies Act2006 and rerx)rt in accordance syith regulalbns made underthose Acts. Ourobiectives are to reasonab a$sUrar aboutwhetherlhe financi statements as awknle arnfree from material missiaiernenL whether due to fraud or &rror, arKI to issue an audilorfs rewrt that indudes our opinion. Reasonable assurance is a high level ot assuranee, txrt Is a guarantee that an audit conducted in acixrdance th ISAS IUW will always dÈtect a rnaterf misstatemeniwhen it exists. Misstatements can arise from fraud or error and are con&dered Materi If. 1ndMduIYorin the aggregate, theyc reasonably be expected to influen¢0 the economicdecisions ot users taken on the tosls oflhese fInaral swements. Irr8gularilies, indL&Jing fraud, are irtstanc8s of non<omp1i8nrÈvth laws and regulations. We design proc&Jures In line ryth our respDnsibilities. oullined 8b¢ve. to deted material misstatements in respect of IrrUlaries. iudIrj fraud. Th8 8xtsntto which wr pyotUreS are capable otdetecting itregularilies, iUdIng tra 15 detail below. 15
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF AGAINST BREAST CANCER GROUP LIMITEDiconthyw YEAR ENDED 31 DECEMBER 2023 WÈ Obtain an understanding of the legal and regulatory frameworks that are applrable to tre entty arKI detemined thai the rnost signthcant are Ise Ihai relate to Ihe Charities SORP. Charrtses Act 2011, Companies Aci 2008, Cod8 01 Fundraising Pra¢bce data protection laws lincludlng UKG8neral Data Protection ReguLation IGDPRII. We assessed the of material misstatement in respeci of Iraud ty Making enquiries ol management and Ih05e charoed with Govemanc? FlewewiTrJ fvaud ri5kfactors within dk%cussion of reLaled party rdatonshry)5 and transaebws Basedvn the resums of ourrlsk assessmentwe designed our audit proceduresto identify nw<Thmplian¢e with such laws and regulations identified abov8. The Group's and Parent CharikNe Companys pdid8s and procedures for compliartè with those 5v5 and regulations was obtained and dtscussed with management. WÈ corrobored our enquiries trjrowh review of bjard meebry minuteg and r8p)rts. No contradittory evhJerK idantified. We considered the risk offraud Ihrough managernenl override and, in reswnsq we In¢orwrated testing of manu lfxJrn entries throughLNrttheyearand accovnling 8S1imaies atlh8 year end into ouraudit8pproa¢h. Bas8d on Ihe resutts of our risk assessmentwe designed our auditproures to identify andto address material misslatements in relation to fraud irrludiTrJ a review ol Ihe atcounting pol95 adopted by the Group and Parent Charitable )mpany partr¢ulaTly in rdation to the recogn0 of Income. W& have considered Ihe extent 10 which the audit was ¢sitIere capable ol detecting irregularities is irtherenltydrfficultwhen dealing yrilh Incoming resources from donation$. The Parentcharitabk Company's Intem control procedures have been des¥Jned to mgate agrtstlhi$ BecaJJse of Ihe inherent limitat8 of an audkt, there is a risk thatwe will not detect &1 irregularities, includSng those leading to a materia misstat8mant in the linanci statsments or non-compiiance witt) reguktion. This risk Irre&s8$ morethat compliance wlh a law or regLJlaiion is removed from lh8 events trans¥bons reffected in the finan¢i& slatem8nts, as we will be less likely to become aware of instances of non-compl1are. The risk is so greater regarding irregulamies oc¢vrring due to fraud ralhpr Ihan error. as fraud invofves intentional 0)ncement, forgery, ¢ollusion, omission or misrepresentation. A lurther description of our reSpObIles for the auclt ol the financi statements Ks located on th8 Finanrizl Reporrino Courol'sweb5iteat:wM¥.frc.Vrg.ujaUdrt0rsreSPDnSIiJth8S. Thi$¢JescriptKJn forms partofouraudilorfs rawrt. USE OFOUR REPORT This rewrt is madtr sdely to th8 tarrtable companls m8mber5. as a bo(ty, in accordant* Chapter 3 of Part 16 of the Companies Act 2006, and to the charttable companvs trystees. as a boty, in accordance witfv Part 4 of the Chari118s and Reports) Regulations2(M)8. raudit wortha5 be8n undertaken sothatsve mightsiate to the tharitable companws m8rnbè@ and InJstee5 those matters we are required to 8tate its them in an auditor report and for no other purpose. To the fullest extent permitted by law, ¥ve (b not accept or assume Trswnsibilty to aryone Olher than the charitable companys mtmbprs as a body and its trustees as a body. for our audit wor forthls report, orforthe opnions we have fomed. HAZEL DAY (Senior Statutgry Audiiorl For and on beh&f ot XEINADIN AUDIT LIMED Chartered Awountants & Stalutory AurtOr 8eckettr House 38 Old Jewry London EQ2R 8DD 16
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING THE INCOME AND EXPENDrfuRE ACCOUTrm YEAR ENDED 31 DECEMBER 2023 Unrestricted Fund5 Total Funds 2023 Toki Fund5 2022 Ftsnds Note ItrICOME AND ENDOWMENTS Donations and Ipgacies Other tradlng acti¥e5 Investment inrxjme CAher income 691,(QO 266,098 1117 150,758 41,838 624,229 250.300 587 2.117 TOTAL INCOME 150,758 1,110,053 875,116 EXPENDITURE ON Raising Funds Chapiiable actNtses Other 1610.7701 13942851 117,4481 {1.022S031 1610.7701 1545,0431 117,4481 11.1732611 1522,39ei 1319,74 115,4211 1857,5641 1150.7581 TOTAL EXPENDuRE 1150.758} NET INCOME AND N MOVEMENT IN FUNDS FOR THE YEAR RECONCILIATION OF FUNDS TotJ fund5 broughl forward TOTAL FUND5 CARRIED FORWARD 10 1632Q81 183,208} 17552 407,197 10,000 417,197 399,645 lo00 417.197 The Staternent of Financi Actiwli88 Indudes &1 gains and losses in the y8ar and therefore a statement of tokl recognised gwns and108ses not b8en prepared. AJI ofthe above arnounts reL4te to continthnu ath68. Thp notes on page$ 23 to 31 torm part of these tlnanclal statements. 17
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF RNANCIAL ACTIVITIES (INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT) YEAR ENDED 31 DECEMBER 2023 Unrestrlcted Funds Rastrlcted Funds Toial Fund5 2023 Tot81 Fu$ 2022 Note INCOME AND ENDOWMENTS Donations and legacies Oiher trading activities Investment Income 0th8r income 1SJ,75B 1.031246 805 2,117 65.OCrfJ 789,629 2.623 587 65,000 11t7 65,000 9W410 TOTAL INCOME 150.758 199,168 857,839 EXPENDITURE ON Costs of generatiw furK1s: Costs of N$ing donation5 and legacies Costs ofcharitable acimbes (Xher 19)3,CrfJS) 1394.2851 114,3281 11,011,618) 1603.0051 1545.0431 114.3281 11.162A761 1509.5861 1319,7471 I10,4) 1150.7581 TOTAL EXPENDITURE 1150,758) 1840,287) NET INCOME AND NET MOVEM IN FUNDS FOR THE YEAR RECONCIUA710N OF FUNDS Total funds broughtforward TOTAL FUNDS CARRIED FOHWARD 10 16&2081 163208 17,552 4107,197 10,0fy) 417,197 399, 1000 353,989 417,197 The Stat8meni of financi activitses includes all g&ns and bsses in ffte year. l ofthe above amounts Late to continuing actwrfaes. The notes on page$ 23 to 31 part of the8efinanclal statement& 18
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CONSOLIDATED BALANCE SHE 31 DECEMBER 2023 2023 XED AssErs Intangible assets Tangible assets 13 14 210,158 309,234 310,159 309,235 CURRENT ASSErs Stocks Debtors Cash at knkarK1 In hand 16 17 23,171 248.395 226.928 18.022 167,096 198,816 498,4¥ 1338,7251 CREDITORS: Amounts tslllng dWhrÈ year 383,934 11TI,5351 18 CURRENT ASSETSIILIABILMES) 159.767 2C6,$99 TOTAL ASSETS LESS CURRENf LIABILITIES 469,926 515,624 CREDOR$. Amounts falllng due •fter more than one year 19 111S,Ydn 353.989 I98,7) 417,197 NEf AS5ETSIILIABILmES) FUNDS Restpicted ircome fUS Unrestricted income funts 10.000 343,989 10,OOD 407,197 24 TOTAL FUNDS 353,989 417,197 The88 ffinal siatements have teen prepared in acCOrdar with the prowisior6 appli¢the to companie$ to the smll companies. regim. These ffinal sktements were approved by the memb&rs of the cOrnnttee and autho for issue on the ..and are signed on their bahalf by.. R Bahu Trustee Dired Company Registration Number. ¥S10215 The notes on pages 23 to 31 fomt part otthesèfinan¢ial slatemen 19
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY BALANCE SHEEr 31 DECEIABER 2023 20TJ 2022 F]XED ASSErs InlanoiblÈ assets Tangible assets Investments 13 14 15 310.158 309,234 310,161 209.237 CuRBEP A5SErs Debtors Cash at bank and in hand 17 266,038 213,563 188.194 178,293 479.601 1319,8361 CREDITORS: Amountsfalllng due wlthln one year 366,487 1160,0901 18 CURReiirASSEfsiiLIABILmESI 159.765 206,397 TOTAL ASSETS LES5 CURREMf UABILMES 469.926 515. CREDITORS: Amourts falllng due afterrnorethan on year 19 1115,93 353,989 198,43n 417,197 NET ASSEfsiiLIABILmESI FUNDS Restricted incom8 funds Unrestricted inctsme funds 10,000 343,989 10,000 407,197 TOTAL FUNDS 253.989 417,197 These finanryd ststements have been w8pared in awordancewnhthe pmiKirts aFpllcabie to ¢ornpanies subje¢t lo the Sm1 companies, regime. These financial Slatements were apprtsv by the members of the commlttee and aulhorised for I&%u8 on the ..and are Signed on their by.. RBah Tnjstee Dire¢ior Company Registration Number.. &310215 The noies on pages 23 to 31 foMI Part of these ffinanelal statements.
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CONSOLIDATED STATEMENT OF CASHFLOWS 31 DECEMBER 2023 20¥8 2022 Cash flows frorn OF4raiing a1vitieS Net income 163.2081 17552 Adiusfm8nts ror.. Depreciatiw ol tangible fixed assets (Xher interest r8ceNable and similar income Interest payable and 5irni&r charges Accrued wen5esllincom81 951 158n 669 1128.11n 1,067 27R87 Ch8ng8s In." Stock Tradp and other d8btors Trade aThJ other creditoks 15,1491 129,6371 99.641 11.9561 110.6321 Cash generated from opÈrabons 28,935 ie1.9021 Interest Interest rec8Ned 11,0671 2.117 16e91 587 Netcash from operating athvtbes 29.9 161,9841 Cash Ilows from Investing 8Ct6vlli¢s Purchase of tangible as8ets 11,8751 Net cash used in irwestiThJ acamtses 11,8751 ¢0sh flows Irom financlng actlvltlas Proceeds from borrowings Nel cash (used inyfrom linanung actN increaselldetreasel in cash and eash equivalar Cash and ea5h equlvalents ai b¢ginnlng otyear Cash and cash equlvolents at end of year 28.110 198,816 161,9841 260.800 226,¥d6 198,816 Noles to the statemÈntof cash 0$ can bpfound In tho notes tothe flnanctal st•ternents page 25-2£. The notes on pages 23 to 31 forni part otthe88financial stalements. 21
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMEwf OF CASHFLOWS 31 DECEMBER 2023 2023 2022 Cash flows from OPBraling aelivitits Net income 163,2081 17552 AdjustmlS for.. Deprèciation ol tangible fixed assets Other interest r8ceNable and similar income Interest payable and sirnilar charges Accmed expensesllincom81 951 12,1171 1,067 2787 726 1587) 669 1141,3531 Chsnges In.. Trade arK1 other debtors Trade and i)ther creditors 126,1821 98,197 18,0781 59229 Cash genernted from 0ratiOnS 36,0 rK1.8421 Interest paid Interest rec8D18d 11,06n 2,117 16691 587 Net¢a5h from operating actiwtses 37.145 (71,Y241 sh Ilows from Investing 8CtMtles Purchase of langible assets 11,8751 Net cash u88d In iwesting aththes 11,8751 Cash flows from flnanelng dctlvltles Proceeds trom borrowings Nei Cash (used in)ltrom linancing actNits8S Increa5elldecreasel In cash and cash equlvalents Cash and cash equients at beglnnlng of yeor Cash and cash equivalents at ènd of year 35,270 178.293 1,9241 250,217 213,563 178,293 Notes to the statsm8ntof Can b8found in ihe notss to the finan¢ial 5tstement$ pagÈ 2>26. The note5 on pages 23 to 31 to part ofthese finèncialstatemems.
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 DECEMBER 2023 Accoui¥llNG POUCIES GeneAI information The chathty is a priate company limited by guarant8e. registered in England and WJes ar a registered tharity in England and WJe&Th8addre8softheregk51er8doffic8 i8 Leathem House, 13 Napiercourt. Barton LanÈ, AlyrKJdon, Oxon, OX14 S. Statement ol eompltance Those finan statsm)ts have been prepar&1 in Lxmpliance th FRS 102. Tre Financia Reporting Standard applicable in thtr UK and lh8 Rapublic of Ireknd.. the Stai&ment of Recomrnendad Practice applicable to CharieS preparing thr accounts in accordanoe wth the Finanra81 Reporting sIard applicable in the UK and Republic of IreLarK1 IFRS 1021 (Charttles SORP IFRS 10211 ett&tive January 2015, Update Bulletin 2 (October 20181 and the Charitvas Act2011. Basi$ of accountlng The financid aternents have been wpared on the historiral o)5t basi%, as modified by the revuaon of certain finala1 assets and liabile5 and inv8slmentproportY85 measured atfar ¥u8 through income orexpenditure. Golng coNM The accounts have been pr8par8d on a grj concarn b&8B. as in the opirion of the Tw5tees. the charity 11 comnue in operation forthe foresÈeatAe futu. Judgements and key sourc0s of esllmaiion un¢ertainty The preparation ofthe finants statements requires managentIO make judgements, e3limates and a55ymplions that aft8cI Ihe arnounts reported. Thes8 esiimales and judgements are continualty reviewed and are bas8d on experience and othertactors, indthaing expectations of future evwts that are bdieved to bp reasOnae under the CIrM8tan¢e5. BHsis of Consolidaiion Th?cons0dHted accounts irthryK)r the resuftsot Against Breast Cancer Umited and itssut6ltharfes Urerta]qng on a line by line b&%ts. The COnlidated entity is referred lo as lh8 Grow),. Incoming Resources l incoming resourtPs are included when Ihe Charity is kgalty enofjed to Ih8 incom& and trE amount can be wantifiwj with rea8onable a(xwracy. Legies are Tecoonts&l when receipt is probable and entitlement is establshed. No amounts are includwj in the Financial Staiementsfors8Mcesdonatedbythe volunteers.Grfts in nd arelnducled at Ihe ree prico or costto th8 donor, if mor8 appropriate. In¢x)me relatin9 to wentstaking place afierth8 yearentl is deferred and in¢luded in the creditors. The rdevantcosts assodated Ihese events are also deferred and ikIded in prepayments. Giftd reclaimed is ac¢¢unted forwh8n r8tynied. Alkleatlon of expenthture Staff costs are apportioned to fUraISing, supw)rL re5earth and LYJv8rnance on a SP8rn bas1$. Depreckqtion incurr8d on fixed assets ler the d)arity's own us8 aThl l0¢ad to Lrsts of g8rÉrating voluntary iwome. 23
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 DECEMBER 2023 Amortlsatlon orbsation rs Calculat so as tD Write off ts (x>st of an assrf less its estlmated re5iduJ v8hJe. over th8 useful economic lrfe of Ihat asset as follows= Patsnts- 25% on cost Ftxeil assets l fixed assets are InitilY r•yJrdad at C)SL Depr8clion The freeho woparty is not depr8ciated as. in th8 orxniDn ofth&Tru&te5. the bu11m9 dem8nt of the vaJu¢ has rvjl dirninished In vdue since aL¥U1SOll. Depreciatiw is cCla so as to wite off the cost of an asset, $& its estimated rasU VU6, over Ihe usefijl acorK)mic life ol at as follows: Equipment- 25% Slra¥Jht Stocks Stocks aT8 valued at Ihe bwer of ¢x)st ard n81 Teaisabl8 VUe. after malong due Var8 for obsolete and slow mo*iro items. Debtors Trade and otherdebtor5 are recognised atthesettlementamounl due afteranytrade Js¢Dunt offered. Prepayments are valued ai the amuni prepad net ofanytrade discounts due. Cash * bank arKI in hand Cash at bank and cash in hand indudes cash arKJ short tem highly liquid investments wilh ashort maturity ofthree month5 or less frorn Ihè date of acquisition oropening of the deposit or5irnilar account. Creditors and provl$lon5 Creditors provEion are rewgnisedwh8re the chanty has a preSent0(gatiOn resullingfrom a pasteventthatwill obabty result in thÈ transler ol funds to a third party and the amount due to setue the obligatn can be measu1 or estimated reliabty. Creditors and provisions ar8 norMty recognis8d ai theiT SetdemeN amount after allDMng for any trade dk8tyJunts dua. Penslons Thè Group operates a defined contribubon pen8ion schÈmp. Contrftrthon$ arecharged in Ihe profrtand105sac0jt asthey betr)me payabl8 in ardance th rules oflhe stheme. Operating Leases Rentals payÈble under operating leases 8r8 Chara in the profit and loss acwunt on a straigm line basis over Ihe 18astr term. Investment pollcy In the Charty bace sheel lh8 invÈsim8nt in the trarfing subsh1i8ry 1$ 5tat&J ato)8t.
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 DECEMBER 2023 VOLUNTARY INCOIAE Group Charity 2023 Group 2022 Charty 2022 Donat10Th5 Donations, gr8rns and grft8 TTUSt income Sportiro Èvents Gitt reclaimed Donation from subsidiary Legacies Legatie5 410.014 13,000 279,951 40261 410,014 13.OL 279,951 tIO261 189,4t 411.(Q4 4,800 153,398 21.784 411,(M14 4,800 153,398 21.784 165,400 98ffj12 98,612 1.031246 33,243 624,9 33,243 789,629 841.&38 2023 income indudes restiicted grants t11j £150,758. 2022 income includes restricted donations tOtlIrj £187,963. Donathjn irLomÈ indudes £NII12022= £Nill in speCtef grfts in donated to the Charity. INCOMING RESOURCES FROM ACTtvmES FOR GENERATING FUNDS Group 20Y6 Charity 2023 Group 2022 Charfty 2022 Recyding intQTne TradiTrJ inc(xne ofsuiw(Sary 805 265,293 266.098 2.623 247.677 2,6td 250,300 2.6¥8 l income 15 UnreStritt for b)th years. OTHER INVESTMW INCOME Group 2023 Charlty 2023 Group 2022 Chanty 2022 Bank Inte$t recewable 2,117 117 587 587 All inwme is unrestiicted forboth years. OTHER INCOME Group 2023 Chavity 2023 Group 20 ChaTity 222 Mawementcharge from subsidiary l incoma k% Unrestrictsdforth years. 65,C4JO 65,000
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMEfrrrs YEAR ENDED 31 DECEMBER 2023 COSTS OF GENERATING VOLUNYARY INCOIIE Group 2023 Charfty 2023 Greup 2022 Charity 2(Y22 Donation$ Event FundraLslng Trading costs of subsidiary SupportC05ts 151,769 227,158 7.765 224,078 810.TIO 151.769 227,158 106,740 202.061 12,810 200,785 106,740 202,061 224,078 603,005 0,785 522,396 509,586 l expeThJiture unrestricted for both years. cosrs oF¢HARABLE ACTNITIES BY FUND TYPE Group 2023 Charlty 2023 Group 2022 Chanty 20 Research 319,747 319,747 Grants of Enll were pwd to iTrINU0l5 in the ye8r to $upport research12022.. £nill. 2023 expendthJre indudes restricta costs t15),758. 2022 eXpenllUre ire5 restritad ¢95ts ttl11rj £187,963. COSTS OF CHARIYABLEA¢nvmES BY ACTNrrY TYPE Voluntary Fundralslng Ev¢nt Fundratslng Support Costs Total 2023 Wages & salaries EmployeTS NI Staff Ppnsion Staf recruitment & trdining Rates & water ghl & heat Insurance Telephone Depreciation StationÈry Publicty Event rnanagoment Databas& costs Travd Propety rewrs & maintenance Agen¢y fees online giwng Miscellaneous Office equiprnent & hardware Postage 202,804 14,210 10.144 6,995 131 169,153 16,346 7.720 6195 820 37157 30,556 17,864 13,990 7,652 1.720 317.567 25.844 15,289 13,872 2,295 516 1,949 in7 476 1,572 5,307 7.620 726 12,275 6,913 42,714 44.147 166 1,299 2,190 $47 95 SN74 951 12A40 13,524 76,218 30,858 570 1,1351 4,976 8,791 21865 53?53 285 1,139 17 715 3,185 200 333 4,461 1,073 3.981 1.788 797 376 7,963 Charity eyencfiture 78.797 280,674 243.534 60&)5 509,586 Trading purthas8s 7,765 7.765 12.810 Growo expendftur6 86,562 280.674 24334 610.770 522,396 2023 expenUre indudes rethcted costs lotsifinu £150.8. 2022 ÈXPEnditur8 indLk1es restricted ojsts tO111J £187,963. 26
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMEMrs YEAR ENDED 31 DECEMBER 2023 OTHER COSTS Group 2023 Charity 2DZJ Group 2022 Charity 2022 Employers NIC Accountary fees Audit fees Legal fees Interest payable Corporatson Ta¥ charge foryear Otherfinancial costs 15.0001 15.0001 15,0001 15,0001 13.628 124 6.183 11,053 1,024 6,183 12.725 1,013 4,222 10,050 1,013 4,222 1,613 2.461 669 17.448 14,328 15,421 10.954 JI e)rture is unrestrfjcted for both year5. 10. INCOMING RESOURCES FOR THE YEAR is slated after charging.. Group 20rJ 2022 Staff penSn ¢ontributions D8preuabon Auditors. remunerat.. - audit ofthe financ Statements 17,864 951 15.439 726 13.628 12.725 Charity 2029 20 Staff penSn contribLthon$ DepatIOn Auditors. remuneration.. - audVtoftt)e financ1 statemÈnts 17,864 951 15,439 726 11.1)53 10,050 11. STAFF COSTS AND EIAOLUMEMrs Total staff costs were as follows: 2023 2022 Wages #t saLgries SOCI secuty costs Other pension (x)sts Redundancy and termination payments 371,957 30,556 17,864 319,312 25,996 15,439 420,377 360.747 Particular5 of ernploye•s: Tre average numb8r of employees dumg the yeer. camlated on the tS offul4ime equivalents, was as follow&: 2023 2022 No No Number of research staft Number of fundraising staff Number of support staff No emF4oyee recved remureralon of more than £60.WO duAr4 theyeaT12022- Nill. No Trustses wero remuneratsd during Ihe year under wew120- Nill
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL sTATEMErs YEAR ENDED 31 DECEMBER 2023 12. TAXATION. GROUP In resp8ct ol Ih? year 2Wd2 T&¥ab"on b&4ed on resutts for the year 13. lIANGIBLE FIXED Assgrs- GROUP AND CHAR Patent COST Al 1 January 23 and 31 Iyecember 2023 2,762 AMORnSATJON At 1 January2023 and 31 Deeember2023 2,761 NET BOOK VALUE At 31 De¢embeT 20TJ At 81 Deceffjb&r2022 1& TANGIBLE FIXED ASSEfs-GROUP AND CHARrrY Freehold prop8rty Equipment Total COST At 1 January 2023 Additions 307.Tr2 39,009 1,875 346.791 1,875 At 31 Deeember 2023 307,782 348,666 DEPRECIATION At 1 J4fjuary 2023 Charge lor the yeaT At31 Dteember 20TJ 3757 951 37A57 951 38,506 NET BOOK VALUE At 31 December2023 307.782 307,782 2A76 1.452 310.158 At 31 December 2022 309,234 15. INVESTMEKrs COST At 1 January 2023 and 31 D8¢ember 2078 NEf BOOK VALUE At31 December 2023 antl 31 D8cerrber2023 County ot incorporation Holding Propjrtion ofvoting rights $hares held Subsldlary undertaknng Aganst Bieasl Cartsr Tradino Limited England inary share io Th8 inveslment presents the cost of 100% of the sfore (apIt of Against Breast Canr Trading knmitod, a company incorporaied in England and Wale5.
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL sTATEME[s YEAR ENDED 31 DECEDABER 2023 16. STOCKS 2022 23.171 18.022 17. DEBTORS Group 2OtJ Charity 2023 Group 2022 Charity 2022 Trade deblors Amounts owed by group undÈrlaknrys er debtors Prepayrnenls 1.403 64599 26.846 1,461 200,141 248W5 2LM).036 140,250 140,250 266,038 167,09S 188,194 18. CREDITORS.. Arnounts falling due wlthin one year Group 2023 Charity 2023 Group 2022 Chartty 2022 Bank loans and overdraft Trade creditors Amounts owed to group undertthngs CorporatiDn Tax Taxation and security Oiher crÈditor5 Accrua 154,961 151070 64R03 62.886 22,516 7A97 153,691 338,725 9,278 7,497 151,191 319036 20,710 379 92,148 7.182 379 89,643 1TK535 160.090 19. CREDITORS.. Amounts falling due after more than one year Group 2023 Charity 2023 Group 2022 Charity 2022 AecruaL% 115,937 115.937 98,437 98,487 I1537 115.937 98,437 20. Analysls of cash and cash equivalents Group 2023 Chaw 20Yd Group 2022 Charity 2022 Cash In Hand 21. Analysls of changes In net debt (Consolidated cash flow slatement} Balanceat 1 January 20ZJ ¢a5h Rows Balance at31 Oecemter 2023 Cash and Cash equivaTents Loans due within l year Leans after 1 year 198,816 28,110 Tot 198016 28.110 221926
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL sTATEME[s YEAR ENDED 31 DECEMBER 2023 22. Analysis of changes In net debt {Charity cash Ilow statement) Balanca at 1 January2023 Cash FJOYS BaJan¢e at 31 December 20YJ Cash and Cash equ1vents Loans due within 1 year Loans after 1 year 178.293 35.270 213A63 Total 178293 35,270 213.563 23. RESTrICTED INCOME FUNDS Balaneeat 1 JOnry 2023 Balance at ExpendItU 31 Dec 2023 Inoome Stewarts Law Foundation The Medtcal Research Counol 10,tKJo 10,000 150,758 11SO,7581 1150,7581 10,0(KJ 150,8 Stewarts Layi Foundatlo Stewarts Law Foundation graTrtedAg•rt BreastCanCer£lO,OtofU1tytatalQguethebl0CQ & urinesampi8& collected during our S year clinieal trial- D$coMLyt. The collection 15 the L8rgosi regourc8 of Tts knnd in tt UK and look approximatety 16 years lo colle¢ The Medlcal Research Council The Medital Research Cwncil repeated their fuNling SUPPOrt again in 2023 to help sustain earlyareer r8searGhers currently 5UPPOrted by Medic res8arch charities. This support. from the Depathent of Business, EnÈrgyand Industri Strate{BEls} and the Departm8ntol Health and SOCI Care IDHSCI, was in recognition ol the I0e$ the research Stsr suffered as a re5utt of Coirid-19. The resumng 'Medic Research Charities Earty Carear ResÈarchers Support Fund, amed lo support and sust*n charity-fund8d researchers earfy on in th8ir Career. Thi5 includ8d PhD students and those with l&ss than 10 years resÈarth experience post-PhD. As a member of the AMRC, Against Breast Cancer We eligble to once again app forthis surport and could nofflinale up 10 10 researchers tt7atwe funded durirvJ the 202212023 finan(ial year. The suCCeful apIcati forthis signrficani grant funding wasvitslio the finartss ol Agwnsl Breas1C2nr and was muth appredat8d bythe IrLBt88s. 24. UNRESTrICTED INCOME FUNDS Bglanco at l Jartuary 2023 IrKoming resources Outgoing Balanceat 31 resources December 2tr l>oup G8neral FurKIs harfjty Gener FurKJ$ 407,197 959,295 948,410 I1,02203) 11,011,618> 343,989 407,197 25. ANALYSIS OF NEf A$ BeYwEEN FUNDS Net current 0$5etsl Iliabllitiesl Long Tenn Llabllltles Inthngible flxed as¥ets Tanglbl8 xed assets Total Group Unr8strfcted In¢¢)me Funds 2023 310,158 159,768 1115.937) 3S3,989
AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMEKrs YEAR ENDED 31 DECEMBER 2023 Charity Unrestri¢ted Irwme Funds 2023 310,160 159,766 1115337) 353.989 Group Restricted Income Ftsrs 20TJ 10,000 10,000 Charity Restricted IrKome Funds 2W23 10,0(K) 10.000 Intanglble fSxed assets eurrent assetsi Illabilitie51 Long Term Llabilltles Tangible flxed assets Group Llnrestri¢ted Incorr* Funds 2022 309,234 16.3041 302,931 Charfty Unrestiicted Income Funds 309,236 16,3061 302,931 Group Restrlcted Income Fd8 2022 10,000 10.000 Charlty R¢strtcted Income Funds 2022 10,000 10.000 26. RELATED PARTYTRANSACTIONS At 31st D8cember 2023 the Charyty was 0 £64,59912022". £46.4831 by its 1W% owned b$1dry. Against 8r8ast Cancer Trading Limited as a result ol trade charges. and charity income rec8ived by the Sudiary bss eXperltsJre inrred on the subsidiary's bèhaw. 27. COMPANY UUITED BY GUARANTEE The Company is limited by guarantee With no issuedshare capltat. There is no ulbwate wntrolling paty. 28. CAprrAL commmENTs At 31 Dec8mber2023 the Company had the authori5 caw wrnrn1lmtsIv1jIrvJ £Nil12022.. £NIll. 29. LEASING COMMrrMENTS Minimum leasè payments under nonwcancellable opèrating leasès fall due as follows:. 2023 2022 Wrthin one year Beeen one and It years Over 5 years 2.385 7,153 2,385 2,385 9.538 31